Macrophage migration inhibitory factor may contribute to vasculopathy in systemic sclerosis

Clinical Rheumatology

Volumn 27, Issue 10, 2008, Pages 1307-1311

  Becker, Heidemarie ^a   Willeke, Peter ^a   Schotte, Heiko ^a   Domschke, Wolfram ^a   Gaubitz, Markus ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Macrophage; Migration inhibitory factor; Pulmonary hypertension; Raynaud's phenomenon; Systemic sclerosis; Vasculopathy

Indexed keywords

AZATHIOPRINE; CYTOKINE; MACROPHAGE MIGRATION INHIBITION FACTOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SCLERODERMA; SYSTEMIC SCLEROSIS; ULCER; VASCULAR DISEASE;

ADULT; AGED; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; HYPERTENSION, PULMONARY; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED; SKIN ULCER; YOUNG ADULT;

EID: 51549116426     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-008-0960-7     Document Type: Article

References (25)

1. Sakkas LI, Chikanza IC, Platsoucas CD (2006) Mechanisms of disease: The role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol 2:679-685
2. Abraham DJ, Varga J (2005) Scleroderma: From cell and molecular mechanisms to disease models. Trends Immunol 26:587-595
3. Bacher M, Metz CN, Calandra T et al (1996) An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 93:7849-7854
4. Calandra T, Bernhagen J, Mitchell RA, Bucala R (1994) The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 179:1895-1902
5. Nishihira J, Koyama Y, Mizue Y (1998) Identification of macrophage migration inhibitory factor (MIF) in human vascular endothelial cells and its induction by lipopolysaccharide. Cytokine 10:199-205
6. Gregersen PK, Bucala R (2003) Macrophage migration inhibitory factor, MIF alleles, and the genetics of inflammatory disorders: Incorporating disease outcome into the definition of phenotype. Arthritis Rheum 48:1771-1776
7. Selvi E, Tripodi SA, Catenaccio M et al (2003) Expression of macrophage migration inhibitory factor in diffuse systemic sclerosis. Ann Rheum Dis 62:460-464
8. Wu S-P, Leng L, Feng Z et al (2006) Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. Arthritis Rheum 54:3661-3669
9. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581-590
10. LeRoy EC, Black C, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 15:202-205
11. Becker H, Maaser C, Mickholz E, Dyong A, Domschke W, Gaubitz M (2006) Relationship between serum levels of macrophage migration inhibitory factor and the activity of antineutrophil cytoplasmic antibody-associated vasculitides. Clin Rheumatol 25:368-372
12. Kahaleh MB (2004) Raynaud phenomenon and the vascular disease in scleroderma. Curr Opin Rheumatol 16:718-722
13. Amin MA, Haas CS, Zhu K et al (2006) Migration inhibitory factor up-regulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 via Src, PI3 kinase, and NFkappaB. Blood 107:2252-2261
14. Mukerjee D, Jap LB, Ong V et al (2004) The myth of pulmonary Raynaud's phenomenon: The contribution of pulmonary arterial vasospasm in patients with systemic sclerosis related pulmonary arterial hypertension. Ann Rheum Dis 63:1627-1631
15. Trad S, Amoura Z, Beigelman C et al (2006) Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 54:184-191
16. Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, Du Bois RM (1997) Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 36:239-243
17. Ho M, Veale D, Eastmond C, Nuki G, Belch J (2000) Macrovascular disease and systemic sclerosis. Ann Rheum Dis 59:39-43
18. Ayoub S, Hickey MJ, Morand EF (2008) Mechanisms of disease: Macrophage migration inhibitory factor in SLE, RA and atherosclerosis. Nat Clin Prac Rheumatol 4:98-105
19. Szucs G, Tímár O, Szekanecz Z et al (2007) Endothelial dysfunction precedes atherosclerosis in systemic sclerosis-relevance for prevention of vascular complications. Rheumatology (Oxford) 46:759-762
20. Scala E, Pallotta S, Frezzolini A et al (2004) Cytokine and chemokine levels in systemic sclerosis: Relationship with cutaneous and internal organ involvement. Clin Exp Immunol 138:540-546
21. Calandra T, Bernhagen J, Metz CN et al (1995) MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377:68-71
22. Wheelhouse NM, Dowidar N, Dejong CH et al (2006) The effects of macrophage migration inhibitory factor on acute-phase protein production in primary human hepatocytes. Int J Mol Med 18:957-961
23. Matsushita T, Hasegawa M, Hamaguchi Y, Takehara K, Sato S (2006) Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: Association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 33:275-284
24. Stavitsky AB, Xianli J (2002) In vitro and in vivo regulation of macrophage migration inhibitory factor (MIF) of expression of MHC-II, costimulatory, adhesion, receptor, and cytokine molecules. Cell Immunol 217:95-104
25. Sato S, Hanakawa H, Hasegawa M et al (2000) Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis. J Rheumatol 27:2838-2842